Q8Z2B3 AF NFT

Glycine--tRNA ligase beta subunit

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeiabwcev2yda6uit66rahbng5bo7liq25xl27f77wk7xtu4up7uin4/metadata.json
IPFS of structure file: 
bafybeia6uaukxse2a32qnojmq7y24fnfiweoh3vibppigibxqqv2agapje/AF-Q8Z2B3-F1-model_v2.pdb
First NFT owner address (eip-55): 
0xbb2A3fB0b56B9d09445eFeB7C267536EF817dd7D
First NFT owner address (bech32): 
genesis1hv4rlv94dwwsj3z7l6muye6ndmup0htag0j2rx
Current NFT ID #447767 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
447767
Accession (UniProt):
Q8Z2B3
Name::
Glycine--tRNA ligase beta subunit
Experimental Method:
Predicted structure
Sequence source:
SALMONELLA TYPHI

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q8Z2B3 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q8Z2B3|SYGB_SALTI Glycine--tRNA ligase beta subunit OS=Salmonella typhi OX=90370 GN=glyS PE=3 SV=3 MSEKTFLVEIGTEELPPKALRSLAESFAANFTAELDNAGLAHGTVQWFAAPRRLALKVANLAEAQPDREIEKRGPAIAQAFDAEGKPSKAAEGWARGCGITVDQAERLTTDKGEWLLYRAYVKGESTEALLPNMVATSLAKLPIPKLMRWGASDVHFVRPVHTVTLLLGDKVIPATILGIQSDRVIRGHRFMGEPEFTIDNADQYPEILRERGKVIADYEERKAKIKADAEEAARKIGGNADLSESLLEEVASLVEWPVVLTAKFEEKFLAVPSEALVYTMKGDQKYFPVYANDGKLLPNFIFVANIESKDPQQIISGNEKVVRPRLADAEFFFNTDRKKRLEDNLPRLQTVLFQQQLGTLRDKTDRIQALAGWIAEQIGADVNHATRAGLLSKCDLMTNMVFEFTDTQGVMGMHYARHDGEAEDVAVALNEQYQPRFAGDDLPSNPVACALAIADKMDTLAGIFGIGQHPKGDKDPFALRRAALGVLRIIVEKNLNLDLQTLTEEAVRLYGDKLTNASVVDDVIDFMLGRFRAWYQDEGYSVDTIQAVLARRPTRPADFDARMKAVSHFRTLEEASALAAANKRVSNILAKATEPLNDIVHASVLKEAAEIELARHLVVLRDKLQPYFADGRYQEALIELAALRAPVDEFFENVMVNAEEKDIRINRLTLLSKLRELFLQVADISLLQ